<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Impel NeuroPharma Presents Data From Phase III Registration Study For The Treatment Of Acute Migraine
Image Overlay - Impel NeuroPharma Presents Data From Phase III Registration Study For The Treatment Of Acute Migraine

Impel NeuroPharma Presents Data From Phase III Registration Study For The Treatment Of Acute Migraine

October 12, 2020

Impel NeuroPharma Presents Data From Phase III Registration Study For The Treatment Of Acute Migraine

Impel NeuroPharma presented patient-reported outcomes data from the company's pivotal phase III, open-label study "STOP 301" of INP104 (dihydroergotamine mesylate) using the company's proprietary POD technology, for the treatment of acute migraine. Yourway is committed to supporting clinical trials for unmet medical needs.

 Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply New England

April 14-15, 2026
Boston, MA

GCSG 2026 US Conference

April 27-29, 2026
San Diego, CA

Media

Articles

White-Glove by Design: The Yourway Standard in Clinical Logistics

Open chat
Come chat with us!
Hello! How can I help you?